Endo Health reports Q3 Branded pharmaceutical sales down 2% to $417M Net sales of Opana ER decreased 36% for the third quarter on 33 percent lower prescriptions. The decrease in Opana ER net sales is primarily a result of the first quarter supply disruption due to the Novartis plant closure in Lincoln, Neb., and a slower return to growth for Opana ER.
News For ENDP From The Last 14 Days
Check below for free stories on ENDP the last two weeks.
Endo shares remain overvalued, says Cantor Cantor Fitzgerald raised its priced target for Endo shares to $52 from $37 ahead of the company's Q2 results, but says the stock remains overvalued. The firm keeps a Sell rating on the name.